Skip to main content
. 2023 Oct 27;77(Supl 3):S1–S7. [Article in Spanish] doi: 10.33588/rn.77S03.2023212

Table II.

Clinical parameters and progress of patients who maintained low-dose safinamide (50 mg/day) (n = 45).

Start Six months p
Morning akinesia, % 75.6 44.2 0.026

Nocturnal akinesia, % 20 12.5 0.046

Wearing off, % 57.8 25.6 0.001

Unpredictable off, % 6.8 4.4 <0.001

UPDRS-III 25.59 (SD: 11.69) 20.89 (SD: 11.52) <0.001

CGI, %
 Better 65.1
 Equal 30.2
 Worse 4.7

CGI: Clinical Global Impression; SD: standard deviation; UPDRS: Unified Parkinson’s Disease Rating Scale.